Literature DB >> 32609943

Intraoral human herpes viruses detectable by PCR in majority of patients.

Tami Yap1,2,3, Shuan Khor1, Jung Seo Kim1, Jaeyoung Kim1, Sung Yun Kim2,3, Johannes S Kern2,3, Raymond Martyres2,3, George Varigos2,3, Hiu Tat Chan4, Michael J McCullough1,3, Melissa L Thomas5, Laura Scardamaglia2,3.   

Abstract

OBJECTIVES: To identify factors which influence the intraoral prevalence of human herpes viruses (HHVs) using mucosal swabs, saliva samples and qPCR analysis.
METHODOLOGY: In this cross-sectional observational study, matched saliva and oral swabs were collected from a total of 115 subjects: 70 immunocompetent subjects with no mucosal abnormalities, 22 with mucosal abnormalities and 23 therapeutically immunocompromised individuals. Extracted DNA was analysed by multiplex qPCR for detection and quantification of HHVs 1-6.
RESULTS: At least one human herpes virus was detected in 77.1% of immunocompetent individuals with no mucosal abnormalities, with EBV the most commonly detected at 61.4%. HHV-6 was detected in 17.1%, HSV-1 in 4.3% and CMV in 1.1%. Detection was higher in saliva than in oral swabs. There was no detection of HSV-2 or VZV. Neither presence of oral mucosal abnormality nor therapeutic immunocompromise was related to increased detection of human herpes virus.
CONCLUSION: Commensal detection rates of EBV are high, and caution in clinical correlation of positive detection is warranted. Commensal CMV rates are low, and detection is likely to be clinically relevant. This study presents a comprehensive commensal detection rate of HHVs 1-6 by qPCR in saliva and swabs.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  Epstein-Barr virus; cytomegalovirus; herpes; oral mucosal disease; saliva; virus

Year:  2020        PMID: 32609943     DOI: 10.1111/odi.13523

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  1 in total

1.  Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.

Authors:  Tal Brosh-Nissimov; Nadav Sorek; Michal Yeshayahu; Irena Zherebovich; Maria Elmaliach; Amos Cahan; Sharon Amit; Erela Rotlevi
Journal:  Vaccine       Date:  2021-08-30       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.